TBPMF - Tetra Bio-Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5092
-0.0107 (-2.07%)
At close: 3:52PM EDT
Stock chart is not supported by your current browser
Previous Close0.5200
Open0.5145
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4944 - 0.5255
52 Week Range0.4350 - 1.1000
Volume54,887
Avg. Volume72,060
Market Cap86.955M
Beta (3Y Monthly)2.32
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire18 days ago

    Tetra Bio-Pharma Names Vice-President, Clinical Programs and Medical Affairs to Its Leadership Team

    Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (TBPMF), a global leader in cannabinoid-derived drug development and discovery today announced the promotion of Aurelia De Pauw to Vice-President, Clinical Programs and Medical Affairs. In her new role Dr. De Pauw will be responsible for of all clinical operations and relations with the medical community, building Tetra Bio-Pharma’s clinical department and ensuring it continues to meet the highest standards of a pharmaceutical company.

  • GlobeNewswire20 days ago

    Tetra Bio-Pharma and Santé Cannabis Announce Completion of the First Phase 2 Cannabis Oil Trial in Cancer and Non-Cancer Patients

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a global leader in cannabinoid-derived drug development and discovery, is pleased to announce completion of the first double-blind, randomized and placebo-controlled Phase 2 clinical trial of cannabis oil capsules. The trial evaluated the safety and efficacy of different doses and ratios of medical cannabis oil comprised of THC and CBD, for the treatment of uncontrolled chronic pain in cancer and non-cancer patients. The Phase 2 trial was conducted by Montreal-based Santé Cannabis, Quebec's first clinical research organization specializing in cannabis and cannabinoids for medical purposes.

  • Two in Three (65%) Canadians Would Take a Drug Containing Cannabis if Prescribed by a Doctor and Covered by Insurance
    CNW Group26 days ago

    Two in Three (65%) Canadians Would Take a Drug Containing Cannabis if Prescribed by a Doctor and Covered by Insurance

    Majority of Canadians (54%) believe taking cannabis for medical reasons without consulting a doctor poses a risk. Knowledge of Canadian clinical trials investigating cannabis medicines is low. Slim majority of Canadians agree that their doctor is informed enough to treat them with cannabis.

  • GlobeNewswirelast month

    The Hemp Energy Drink arrives in store!

    Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (TBPMF), announces that Hemp Energy Drink cans are now available in 59 grocery stores and convenience stores in British Columbia, Alberta, and Saskatchewan. In British Columbia the Hemp Energy Drink is available to consumers in Vancouver, Balfour, Burnaby, Castlegar, Clearwater, Grand Forks, Hope, Houston, Kaslo, Keremeos, Ladner, Langley, Lillooet, Nanaimo, Nelson, North Vancouver, Oliver, Osoyoos, Port Alberni, Robson, Rossland, Salt Spring Island, Simon Fraser University, Slocan Park, Squamish, Summerland, Surrey, Trail, Vernon, Victoria, West Kelowna, Whistler and White Rock. In Alberta, the Hemp Energy Drink can be found in Athabasca, Banff, Boyle and Langdon, and in Saskatchewan in Kindersley and Tisdale.

  • GlobeNewswirelast month

    Tetra Bio-Pharma Provides Update on its Neuropathic and Chronic Pain Drug Development Program

    A Phase 1 study in healthy volunteers using vaporized PPP001 was successfully completed (click here) and the Corporation filed a patent application after unexpectedly discovering the unique composition of cannabis smoke.  In July 2018, the Corporation entered into a co-development agreement with Storz & Bickel, widely recognized as the global leader in vaporizer design and manufacturing. Tetra incorporated the vaporizer into its smoke-vapor research program as it aimed to understand how inhaled cannabis relieves pain for patients.

  • GlobeNewswirelast month

    Tetra Bio-Pharma Announces Stock Option Grants

    Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (TBPMF), announces today that it has granted, pursuant to the Company's stock option plan (the "Plan"), 375,000 options to officers of the Company. Each option entitles its holder to purchase one common share of the Company. All of the options are subject to the terms of the Plan and the requirements of the TSX Venture Exchange.

  • GlobeNewswirelast month

    Tetra Bio-Pharma Pursues Its Research Priorities Accelerating Other Drug Development Plans

    Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (TBPMF), a global leader in cannabinoid-derived drug development and discovery, today announced a change in their Drug Development Plan (DDP) priorities. This will allow Tetra to rapidly leverage the PANAG pipeline and expertise and align its research programs on indications with unmet medical needs or a higher return on investment (ROI).  Through an expanded and focused pipeline, the Corporation intends to maintain its position as a leader in cannabis and cannabinoid drug development with a clear objective to generate value for shareholders.  In addition to its DDP in oncology and neuropathic pain programs, Tetra will pursue the development of prescription products in ophthalmic, dermatology as well as other pain segments.

  • GlobeNewswire2 months ago

    Tetra Bio-Pharma Redefines Quality Standards for Pharmaceutical Grade Cannabis-Derived Products

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), today announced that it has temporarily suspended its phase 3 clinical program due to impurities found in its PPP001 investigational drug being administered to patients.  This suspension does not affect the timing of the European application nor the development of the second-generation inhalation products. Quality standards and process validations are imposed by pharmaceutical Good Manufacturing Practices (GMP).  Just like our food chain, botanical drugs have unique challenges because of the potential for microbial contamination known as mycotoxins.  Tetra’s investigational drug is composed of raw cannabis materials.

  • CNW Group2 months ago

    Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra's Dermatology Product Portfolio

    LAVAL, QC , and ORLEANS, ON , Feb. 4, 2019 /CNW/ - Crescita Therapeutics Inc. ("Crescita") (CTX.TO), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, ("Tetra") (TBP.V) (TBPMF) today announced an agreement to develop an enhanced version of Tetra's dermatology portfolio using Crescita's patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ("MMPE™") and DuraPeel™. The primary active ingredient contained in the product portfolio to be reformulated is beta-caryophyllene ("Beta-C"), which is known to work on Cannabidiol ("CBD") 2 receptors.

  • GlobeNewswire2 months ago

    Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio

    Crescita Therapeutics Inc. ("Crescita") (CTX.TO), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, ("Tetra") (TBP.V) (TBPMF) today announced an agreement to develop an enhanced version of Tetra’s dermatology portfolio using Crescita’s patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ("MMPE™") and DuraPeel™. The primary active ingredient contained in the product portfolio to be reformulated is beta-caryophyllene ("Beta-C"), which is known to work on Cannabidiol ("CBD") 2 receptors. The testing methodology and the clinical development made possible by the collaboration will help optimize the delivery of Beta-C and several other active ingredients into the skin and local tissues.

  • CNW Group2 months ago

    Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc.

    ORLEANS, ON , Jan. 30, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TBP.V) (TBPMF), today announced it has entered into a definitive agreement (the "Agreement") with the shareholders (the "Vendors") of Panag Pharma Inc. ("Panag") for the previously-announced acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the "Proposed Transaction").  Panag is a Canadian-based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation.  Panag has developed innovative and patented formulations for the treatment of ocular diseases and other pain conditions such as general neuropathic pain.

  • GlobeNewswire2 months ago

    Tetra Bio-Pharma Files Patent Application to Protect PPP001

    Tetra Bio-Pharma Inc (“Tetra” or the “Company”) (TSX VENTURE: TBP) (TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it filed a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that has enabled the company to apply for patent protection.

  • GlobeNewswire2 months ago

    Tetra Natural Health Adds New Leaders to its Commercial Operations

    Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (TBPMF), is pleased to announce that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics. Derek Theriault, National Sales Director – has 20 years’ experience within the pharmaceutical industry and has held various sales and leadership roles during this time.

  • CNW Group2 months ago

    The Lung Association - Ontario and Tetra Bio-Pharma partner to help fill the gaps in cannabis research

    TORONTO , Jan. 10, 2019 /CNW/ - With the recent legalization of recreational cannabis in Canada , a major gap has been revealed, and that is a lack of scientific research on the health effects of its use – both on the recreational and medical side. The Lung Association – Ontario and Tetra Bio-Pharma are excited to be partnering to fill that gap by funding a research program that will investigate various health impacts of cannabis use. The goal of this program will be to better support patients and healthcare providers with evidence-based information.

  • GlobeNewswire4 months ago

    Tetra Bio-Pharma in Process of Filing Patent Application Exceeding its Data Protection Initial Assumption for its PPP001

    Tetra Bio-Pharma Inc (“Tetra” or the “Company”) (TSX VENTURE: TBP) (TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it is in process of filing a patent application for its PPP001 drug product.  Tetra’s research has led to a significant discovery that allows for patent protection. “This patent application, if granted, would provide Tetra with full protection of its PPP001 prescription drug product.  This will put PPP001 in the same category as any other innovative prescription drug,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma.

  • GlobeNewswire4 months ago

    Tetra Bio-Pharma Responds to Shareholders

    Tetra Bio-Pharma Inc (“Tetra” or “TBP”), (TSX VENTURE: TBP) (TBPMF) - Recent news regarding Aphria Inc. does not in any way affect Tetra’s business, operations, clinical and drug registration and source of supply. “It’s important for our shareholders to understand that Tetra is not a cannabis company.

  • GlobeNewswire4 months ago

    Tetra Bio-Pharma Convenes First National Medical Advisory Board

    Tetra Bio-Pharma Inc (“Tetra” or “TBP”), (TSX VENTURE: TBP) (TBPMF), – announced that it held its first National Advisory Board meeting in Toronto, on November 30, 2018 as a platform to validate their drug development and commercial programs. “I am confident that this will be the first of many transparent and collaborative exchanges that Tetra organizes with physicians as we seek to bring cannabinoid-derived medicines into our healthcare system,” said Steeve Neron, Senior Vice-President, Marketing and Medical Affairs. Tetra Bio-Pharma (TBP.V) (TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.

  • GlobeNewswire4 months ago

    Tetra Natural Health Will Deliver 20 containers of Hemp Energy Drink to Meet Consumer Demand

    Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (TBPMF), announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink, the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country. Canadian consumers appreciate the qualities of Hemp Energy Drink (www.hempenergydrink.ca) that contains fewer calories and more natural ingredients than other energy drinks, and the product will be available soon everywhere in Canada in three flavors: classic, mango and raspberry.

  • GlobeNewswire4 months ago

    Tetra Bio-Pharma Closes Financing With Aphria Inc.

    Tetra Bio-Pharma Inc (“Tetra” or “TBP”), (TSX VENTURE: TBP) (TBPMF), has closed a private placement of units (the “Private Placement”) with its strategic partner Aphria Inc. (“Aphria”) (APHA.TO) (APHA). Under the Private Placement, Tetra issued to Aphria (6,900,000) units (the “Units”), with each unit being comprised of one Class A common share of Tetra (a “Common Share”) and one Common Share purchase warrant (a “Warrant”), at a price of $1.03 per unit, which is the closing price of the Common Shares on the TSX Venture Exchange on November 28, 2018, for gross proceeds of $7,107,000.

  • GlobeNewswire4 months ago

    Tetra Bio-Pharma’s Dr. Chamberland Goes to Washington!

    Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), is pleased to update the market that Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C. today for individual meetings with six high-ranking U.S. Senators. The meetings, scheduled for November 26th and 27th, have a mutually beneficial purpose, namely expanding Tetra’s existing work with Health Canada and the FDA in the United States as well as briefing the Senators on Tetra Bio-Pharma’s unique approach which combines the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

  • GlobeNewswire4 months ago

    Tetra Bio-Pharma Enters into Binding Proposal with Quantum Pharma Inc.

    ORLEANS, Ontario, Nov. 20, 2018 -- Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Quantum Pharma Inc. (“Quantum”) today announced the signing.